25 enrolling by invitation. 25 Phase 3, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 25 | Enrolling by invitation 25 |
| Phase 2 | 10 | Enrolling by invitation 10 |
Follow Neoplasms: new trials by email Literature Review of Neoplasms trials Research Report on Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study Cabozantinib, Zanzalintinib, Atezolizumab - Cancer, Renal Cell Carcinoma (RCC) | Phase 3 | Enrolling by invitation | Exelixis | 5000 | 2026-07-30 | 2026-10-28 |
| VEN+IDAC vs IDAC in AML Ventoclax, Cytarabine - AML (Acute Myelogenous Leukemia) | Phase 2 / Phase 3 | Enrolling by invitation | Guangdong Second Provincial General Hospital | 232 | 2026-04-01 | 2026-04-17 |
| Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Daunorubicin+cytarabine - Acute Myeloid Leukemia, Lisaftoclax | Phase 2 / Phase 3 | Enrolling by invitation | First Affiliated Hospital of Zhejiang University | 267 | 2026-03-01 | 2026-06-16 |
| Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Lisaftoclax+azacitidine - Acute Myeloid Leukemia (AML), Lisaftoclax | Phase 2 / Phase 3 | Enrolling by invitation | First Affiliated Hospital of Zhejiang University | 450 | 2026-03-01 | 2026-06-16 |
| Investigation of Effect of Formulated Methylene Blue on Treatment of Squamous Cell Carcinoma Skin Cancer in Inoperable Patients and Not Suitable for Radiotherapy Formulated Topical Methylene Blue (0.5 mg/mL), Wound Healing Gel - SCC - Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma of Skin | Phase 3 | Enrolling by invitation | Daryoush Hamidi Alamdari, PhD | 20 | 2025-12-20 | 2026-01-06 |
| Treatment of Basal Cell Carcinoma (BCC) of the Skin, of the Morpheiform, Infiltrative, and Noduloulcerative Types in Inoperable Patients and Not Suitable for Radiotherapy Using Formulated Methylene Blue Formulated Topical Methylene Blue (0.5 mg/mL), Wound Healing Gel - Advanced Basal Cell Carcinoma (BCC), Inoperable Disease | Phase 3 | Enrolling by invitation | Daryoush Hamidi Alamdari, PhD | 20 | 2025-10-21 | 2026-01-06 |
| Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TNBC） paclitaxel polymeric micelles + carboplatin + iparomilimab and tuvonralimab - Triple-Negative Breast Cancer (TNBC), Neoadjuvant Therapy | Phase 2 / Phase 3 | Enrolling by invitation | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 32 | 2025-07-21 | 2026-08-18 |
| An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis Zilucoplan - Generalized Myasthenia Gravis | Phase 3 | Enrolling by invitation | UCB Biopharma SRL | 8 | 2024-11-19 | 2026-10-02 |
| A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer Rulonilimab, Placebo, cisplatin/carboplatin + paclitaxel ± bevacizumab - Cervical Cancer | Phase 2 / Phase 3 | Enrolling by invitation | Shandong New Time Pharmaceutical Co., LTD | 510 | 2024-09-26 | 2025-01-01 |
| Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy Sintilimab Combined With Docetaxel Monotherapy - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | Enrolling by invitation | Ye jinjun | 79 | 2024-08-01 | 2025-06-12 |
| A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma R-CHOP, Decitabine in combination with R-CHOP - Lymphoma, Large-Cell, Diffuse | Phase 3 | Enrolling by invitation | Second Affiliated Hospital of Nanchang University | 80 | 2024-07-01 | 2026-01-16 |
| Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion. PLB1004, Pemetrexed+（carboplatin or Cisplatin）with or without Sintilimab - Non-Small-Cell Lung Cancer | Phase 3 | Enrolling by invitation | Avistone Biotechnology Co., Ltd. | 327 | 2023-12-01 | 2026-04-23 |
| Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Biliary Obstruction Primary percutaneous stenting (PPS), Endoscopic biliary drainage - Cholangiocarcinoma Non-resectable, Gall Bladder Cancer | Phase 3 | Enrolling by invitation | Erasmus Medical Center | 148 | 2023-08-09 | 2024-11-04 |
| Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients venetoclax - Acute Promyelocytic Leukemia | Phase 2 / Phase 3 | Enrolling by invitation | The First Affiliated Hospital of Soochow University | 98 | 2023-08-01 | 2024-08-09 |
| Evaluating the Efficacy of Chidamide in the Treatment of Initial Unresectable Metastatic Colorectal Cancer With High Expression of SULF1 Patients receive standard second-line therapy combined with oral chidamide, standard second-line therapy - Colorectal Cancer | Phase 2 / Phase 3 | Enrolling by invitation | Sir Run Run Shaw Hospital | 126 | 2023-06-01 | 2026-11-09 |
| Evaluating the Efficacy of Chidamide in Advanced Refractory Colorectal Cancer With High SULF1 Expression Oral chidamide treatment - Colorectal Cancer | Phase 2 / Phase 3 | Enrolling by invitation | Sir Run Run Shaw Hospital | 17 | 2023-06-01 | 2026-11-09 |
| Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome Fludarabine and Busulfan, Fludarabine and Melphalan - Acute Myeloid Leukemia, Adult, Myelodysplastic Syndrome(MDS) | Phase 3 | Enrolling by invitation | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 200 | 2023-02-15 | 2025-02-10 |
| Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study TOL2506, Tamoxifen, Letrozole tablets - Breast Cancer | Phase 3 | Enrolling by invitation | Tolmar Inc. | 250 | 2022-12-28 | 2026-10-23 |
| Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis Efgartigimod IV or Efgartigimod PH20 SC - Generalized Myasthenia Gravis, gMG | Phase 2 / Phase 3 | Enrolling by invitation | argenx | 12 | 2022-08-18 | 2026-11-03 |
| Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab Durvalumab - Cancer | Phase 3 | Enrolling by invitation | AstraZeneca | 214 | 2022-04-19 | 2026-10-26 |
Showing 20 of 25. Sign in to see all of them.
Leukemia, Myeloid, Acute (5) · Carcinoma, Non-Small-Cell Lung (3) · Colorectal Neoplasms (3) · Myasthenia Gravis (2) · Prostatic Neoplasms (2) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Basal Cell (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Esophageal Squamous Cell Carcinoma (1) · Gallbladder Neoplasms (1) · Leukemia, Promyelocytic, Acute (1)
Neoplasms by Site (14) · Neoplasms by Histologic Type (12) · Hemic and Lymphatic Diseases (8) · Hematologic Diseases (6) · Leukemia (6) · Leukemia, Myeloid (6) · Digestive System Diseases (5) · Digestive System Neoplasms (5) · Gastrointestinal Diseases (4) · Gastrointestinal Neoplasms (4) · Immune System Diseases (4) · Neoplasms, Glandular and Epithelial (4) · Bronchial Neoplasms (3) · Carcinoma (3)
Carboplatin (3) · Cisplatin (2) · Cytarabine (2) · Induction Chemotherapy (2) · Opiate Substitution Treatment (2) · Prednisone (2) · Afatinib (1) · Anastrozole (1) · Azacitidine (1) · Brentuximab Vedotin (1) · Busulfan (1) · Cyclophosphamide (1) · Decitabine (1) · Dexamethasone (1) · Doxorubicin (1)
Daryoush Hamidi Alamdari, PhD (2) · First Affiliated Hospital of Zhejiang University (2) · Sir Run Run Shaw Hospital (2) · Asan Medical Center (1) · AstraZeneca (1) · Avistone Biotechnology Co., Ltd. (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Chinese Academy of Medical Sciences (1) · Erasmus Medical Center (1) · Exelixis (1) · Guangdong Second Provincial General Hospital (1) · Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (1) · N.N. Petrov National Medical Research Center of Oncology (1) · Second Affiliated Hospital of Nanchang University (1) · Shandong New Time Pharmaceutical Co., LTD (1)
China (15) · United States (4) · Canada (3) · Poland (3) · South Korea (3) · United Kingdom (3) · Argentina (2) · Belgium (2) · Brazil (2) · France (2) · Germany (2) · India (2) · Iran (2) · Italy (2) · Mexico (2)
Je-Hwan Lee, MD (1) · Linghui Xia, Professor (1) · Yuankai Shi (1)
2023 (1)